- Home
- MRM vs COCP Comparison
MRM vs COCP Comparison
Compare MRM & COCP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | MRM | COCP |
|---|---|---|
| Founded | 2000 | 2006 |
| Country | Japan | United States |
| Employees | N/A | N/A |
| Industry | Other Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 15.8M | 15.3M |
| IPO Year | 2020 | N/A |
Fundamental Metrics
Financial Performance| Metric | MRM | COCP |
|---|---|---|
| Price | $1.34 | $0.96 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $6.00 |
| AVG Volume (30 Days) | 49.8K | ★ 92.2K |
| Earning Date | 05-22-2026 | 11-14-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.04 | N/A |
| Revenue | ★ $55,915,220.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $31.54 | ★ N/A |
| Revenue Growth | ★ 12.79 | N/A |
| 52 Week Low | $0.34 | $0.86 |
| 52 Week High | $4.45 | $2.67 |
Technical Indicators
Market Signals| Indicator | MRM | COCP |
|---|---|---|
| Relative Strength Index (RSI) | 17.53 | 45.31 |
| Support Level | $1.21 | $0.86 |
| Resistance Level | $1.73 | $0.99 |
| Average True Range (ATR) | 0.09 | 0.06 |
| MACD | -0.02 | -0.01 |
| Stochastic Oscillator | 23.02 | 47.47 |
Price Performance
Historical ComparisonAbout MRM MEDIROM Healthcare Technologies Inc.
MEDIROM Healthcare Technologies Inc provides health services. The company is a franchiser and operator of healthcare salons and operates in segments namely Relaxation Salon, Digital Preventative Healthcare, and Luxury Beauty Segment. The company generates a majority of its revenue from the Relaxation Salon business segment. Geographically, the company generates a maximum share of its revenue from Japan.
About COCP Cocrystal Pharma Inc.
Cocrystal Pharma Inc is a biotechnology company discovering and developing novel antiviral therapeutics that target the replication machinery of influenza viruses, hepatitis C viruses, and noroviruses. It employs structure-based technologies and Nobel Prize-winning expertise to create first and in-class antiviral drugs. It is developing CC-31244, an investigational, oral, broad-spectrum replication inhibitor called a non-nucleoside inhibitor (NNI).